TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06672991

Intervention type: PROCEDURE
Intervention: Endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy
Description: Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis, 7 to 15 days after ERCP in a single hospitalization

Intervention type: PROCEDURE
Intervention: Endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy
Description: Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patient underwent the endoscopic procedure using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis for readmission, 1 month after ERCP under general anesthesia.
Study: NCT06671379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009 monotherapy
Description: SHR-A2009 monotherapy ，SHR-A2009 will be administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platinum-based dual-agent chemotherapy
Description: Pemetrexed combined with carboplatin or cisplatin, after four cycles of combination, pemetrexed was continued as a single agent，all drugs will be administered intravenously
Study: NCT06588634

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FlowTriever System
Description: Mechanical thrombectomy for pulmonary embolism

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care treatment for pulmonary embolism
Study: NCT06296979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phrenic nerve neuromodulation
Description: The intervention group will receive the usual physiotherapy treatment at the health center and will also receive neuromodulation on the phrenic nerve at its exit through the anterior cervical region. The neuromodulation technique will be applied for 10 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: common Physical therapy
Description: the usual treatment of the center consisting of manual therapy, exercise and thermotherapy will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: common Physical therapy
Description: the usual treatment of the center consisting of manual therapy, exercise and thermotherapy will be performed.
Study: NCT05744895

Intervention type: DEVICE
Intervention: Device: Robotic MAKO total knee
Description: Prospective TKA patient receiving total knee arthroplasty using the MAKO robotic machine

Intervention type: DEVICE
Intervention: FocusMotion knee brace
Description: Focusmotion knee brace measures range of motion during exercises

Intervention type: DEVICE
Intervention: Fitbit tracking device
Description: Fitbit will measure patients steps, HR, and sleep

Intervention type: DEVICE
Intervention: FocusMotion app
Description: Will survey patients with PROMS
Study: NCT04335682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darolutamide
Description: Patients randomized to darolutamide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Patients randomized to enzalutamide.
Study: NCT06368479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStatis HBsAg Test
Description: Capillary (fingerstick) blood, EDTA venous whole blood, serum and plasma samples to be tested on the iStatis HBsAg Test at the point of care setting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStatis HBsAg Test
Description: Capillary (fingerstick) blood, EDTA venous whole blood, serum and plasma samples to be tested on the iStatis HBsAg Test at the point of care setting.
Study: NCT05582499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin
Study: NCT04849910

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VOR33
Description: Allogeneic, human leukocyte antigen (HLA) matched, genome edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 myeloid protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VOR33
Description: Allogeneic, human leukocyte antigen (HLA) matched, genome edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 myeloid protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VOR33
Description: Allogeneic, human leukocyte antigen (HLA) matched, genome edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 myeloid protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg
Description: Infusion of Mylotarg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg
Description: Infusion of Mylotarg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg
Description: Infusion of Mylotarg
Study: NCT05683795

Intervention type: OTHER
Intervention: Consensus study
Description: Modified-Delphi study and consensus meetings
Study: NCT05582499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide
Study: NCT05434195

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arcofolin® 5-Methyltetrahydrofolate
Description: 5-methyltetrahydrofolate (5-MTHF) is the biologically active form of reduced folate, which can increase BH4 availability. 5-MTHF is available as a nutritional vitamin (Merck \& Cie) for human use including during pregnancy. Two out of three preeclamptic study groups will receive 5-MTHF - one at a low dose and the other at a high dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arcofolin® 5-Methyltetrahydrofolate
Description: 5-methyltetrahydrofolate (5-MTHF) is the biologically active form of reduced folate, which can increase BH4 availability. 5-MTHF is available as a nutritional vitamin (Merck \& Cie) for human use including during pregnancy. Two out of three preeclamptic study groups will receive 5-MTHF - one at a low dose and the other at a high dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Arcofolin® Placebo
Description: The placebo, this consists of the same excipients as 5-MTHF, microcrystalline cellulose and silica with no active ingredient.
Study: NCT04932655

Intervention type: DRUG
Group type: OTHER
Intervention: simufilam
Description: Simufilam 100 mg oral tablets: the Phase 3 oral tablet for the first 3 arms and the Phase 2 tablet for the 4th arm.

Intervention type: DRUG
Group type: OTHER
Intervention: simufilam
Description: Simufilam 100 mg oral tablets: the Phase 3 oral tablet for the first 3 arms and the Phase 2 tablet for the 4th arm.

Intervention type: DRUG
Group type: OTHER
Intervention: simufilam
Description: Simufilam 100 mg oral tablets: the Phase 3 oral tablet for the first 3 arms and the Phase 2 tablet for the 4th arm.
Study: NCT05582499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide
Study: NCT04932655

Intervention type: DRUG
Group type: OTHER
Intervention: simufilam
Description: Simufilam 100 mg oral tablets: the Phase 3 oral tablet for the first 3 arms and the Phase 2 tablet for the 4th arm.
Study: NCT04871048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) active
Description: Stimulation will be performed using a Neurocan DC-Stimulator Plus with two 7×5 cm sponge electrodes soaked in a saline solution. Electrodes will be placed in accordance with the international 10-20 electrode placement system: the anode over F4 (right DLPFC), the cathode over Fp1 (MPFC). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day (separated by at least 3 hours) for 5 consecutive weekdays.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) non active
Description: The control group will receive the sham stimulation following the same regimen, using the sham procedure which has been developed by the manufacturer of the tDCS material, allowing sensations to be felt in the scalp which are the equivalent to those of the active stimulation. The same device will be used for both the sham and the active procedures.
Study: NCT04943328

Intervention type: DEVICE
Group type: OTHER
Intervention: Total Hip Arthroplasty
Description: cemented hip arthroplasty
Study: NCT06220461

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Infants allocated to the intervention group will receive folic acid (50 mcg flat dose/day) starting at 14 days of age.
Study: NCT06529263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: newborn massage
Description: Newborn massage is one of the complementary treatment methods that support the treatment and contribute to the development of the baby
Study: NCT06417996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Group
Description: Once patients are ready for discharge, patients in the digital group will be sent home with the Biobeat digital monitoring kit with written \& oral instructions on how it will be used in maintaining continuity of care which will track ECG (electrocardiogram), HR, NIBP, SPO2, and pain scores. A continuous recording and two-lead ECG patch will be applied and activated at the time of discharge to identify any paroxysmal atrial fibrillation.
Study: NCT05236075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shearing wave collar
Description: Collar inducing shearing wave to treat obstructive sleep disorders
Study: NCT05522608

Intervention type: PROCEDURE
Intervention: transabdominal preperitoneal hernia repair
Description: It is made through 3 holes, 10 mm optical port from the umbilicus, and 5 mm ports each from the right and left lower quadrants. The peritoneum is opened a few cm above the defect in the form of an arc. Dissection of the peritoneum, first lateral and then medial to the defect, is performed. It is continued until the pubic bone is found medially and the periphery of the bone is released. The dissection of the cord elements and the sac is completed. Posterior dissection is a very important step to avoid recurrence. Here, the peritoneum is thoroughly dissected posteriorly, the ductus deferens and vessels are removed from the peritoneum so that no recurrence occurs under the patch. 1-2 to the pubic tubercle, 3-5 to the upper edge of the patch, to the upper edge. Staples at the upper edge should remain above the iliopubic tract, no staples should be placed below. The patch is closed by overlapping the peritoneal leaves so that the patch is not visible.

Intervention type: PROCEDURE
Intervention: transabdominal preperitoneal hernia repair
Description: It is made through 3 holes, 10 mm optical port from the umbilicus, and 5 mm ports each from the right and left lower quadrants. The peritoneum is opened a few cm above the defect in the form of an arc. Dissection of the peritoneum, first lateral and then medial to the defect, is performed. It is continued until the pubic bone is found medially and the periphery of the bone is released. The dissection of the cord elements and the sac is completed. Posterior dissection is a very important step to avoid recurrence. Here, the peritoneum is thoroughly dissected posteriorly, the ductus deferens and vessels are removed from the peritoneum so that no recurrence occurs under the patch. 1-2 to the pubic tubercle, 3-5 to the upper edge of the patch, to the upper edge. Staples at the upper edge should remain above the iliopubic tract, no staples should be placed below. The patch is closed by overlapping the peritoneal leaves so that the patch is not visible.
Study: NCT04960696

Intervention type: DIAGNOSTIC_TEST
Intervention: OSDI
Description: Change of OSDI in distance education

Intervention type: DIAGNOSTIC_TEST
Intervention: OSDI
Description: Change of OSDI in distance education

Intervention type: DIAGNOSTIC_TEST
Intervention: OSDI
Description: Change of OSDI in distance education

Intervention type: DIAGNOSTIC_TEST
Intervention: OSDI
Description: Change of OSDI in distance education
Study: NCT05005195

Intervention type: RADIATION
Group type: OTHER
Intervention: Low dose abdominal computed tomography scan
Description: A policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer
Study: NCT04960696

Intervention type: DIAGNOSTIC_TEST
Intervention: tear break up time
Description: Change of tear break up time in distance education

Intervention type: DIAGNOSTIC_TEST
Intervention: tear break up time
Description: Change of tear break up time in distance education

Intervention type: DIAGNOSTIC_TEST
Intervention: tear break up time
Description: Change of tear break up time in distance education

Intervention type: DIAGNOSTIC_TEST
Intervention: tear break up time
Description: Change of tear break up time in distance education

Intervention type: DIAGNOSTIC_TEST
Intervention: schirmer
Description: Change of schirmer in distance education

Intervention type: DIAGNOSTIC_TEST
Intervention: schirmer
Description: Change of schirmer in distance education

Intervention type: DIAGNOSTIC_TEST
Intervention: schirmer
Description: Change of schirmer in distance education

Intervention type: DIAGNOSTIC_TEST
Intervention: schirmer
Description: Change of schirmer in distance education
Study: NCT05582499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: tyrosine kinase inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: tyrosine kinase inhibitors
Study: NCT06679231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: After the initial measurements of the participants assigned to the experimental group, the students involved in the project will accompany the patient and prepare the patient for the gynecological examination. To make the patient feel more comfortable during the gynecological examination, she will be given two stress balls. The patient will be asked to count each time she squeezes the stress ball during the examination. During the gynecological procedure, the participant will be administered the first EC-3. The stress ball intervention will help to reduce the participant's anxiety level and make the examination process more tolerable. In addition, the student's support to the patient will make the examination more comfortable and contribute to the participant's psychological well-being.
Study: NCT06664879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG-453 + Azacitidine
Description: Given intravenously (by vein)
Study: NCT06626139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Healthy participants will receive up to 25 mg psilocybin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Healthy participants will receive up to 25 mg psilocybin.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Context 1
Description: Drug administration will take place in a context (Context 1) that is expected to modulate acute and post-acute drug effects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Context 1
Description: Drug administration will take place in a context (Context 1) that is expected to modulate acute and post-acute drug effects.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Context 2
Description: Drug administration will take place in a context (Context 2) that is expected to modulate acute and post-acute drug effects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Context 2
Description: Drug administration will take place in a context (Context 2) that is expected to modulate acute and post-acute drug effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy participants will receive an inactive placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy participants will receive an inactive placebo.
Study: NCT06684041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 capsule
Description: HRS-5965 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 capsule
Description: HRS-5965 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 capsule
Description: HRS-5965 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 capsule placebo
Description: HRS-5965 capsule placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 capsule placebo
Description: HRS-5965 capsule placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 capsule placebo
Description: HRS-5965 capsule placebo
Study: NCT06681909

Intervention type: BEHAVIORAL
Intervention: UB Campus Veggie Van
Description: The UB Veggie Van is based on the Veggie Van, an evidence-based mobile produce market intervention. Mobile markets are like farmers' markets on wheels that travel to underserved communities selling high-quality, low-cost produce and healthy foods. The Veggie Van mobile market model was developed through multiple research studies on the efficacy, effectiveness, and implementation of the intervention, and is a multi-level intervention that addresses the five components of nutrition security (availability, accessibility, affordability, stability, and utilization). The UB Veggie Van is operated according to the Veggie Van model, with specific adaptations made to more effectively reach the campus community (Aim 1 of the larger funded study).
Study: NCT06145763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Use iCanQuit smartphone app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention
Description: Use NCI QuitGuide smartphone app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06627296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Individuals in the NMES group will have a total of 24 sessions of NMES application with 15 repetitions 3 days a week for 8 weeks and then exercise programs will be performed face-to-face. They will also be given home exercises to continue at home.~In the NMES group, NMES training will be performed for extensor carpi radialis longus (ECRL), extensor carpi radialis brevis (ECRB), abductor pollicis longus (APL), flexor carpi radialis (FCR) muscles. The pencil electrode will be used to stimulate the ECRL, ECRB, FCR and APL muscles in such a way that 30+30+30=90 contractions will be obtained from each muscle. According to the morphologic characteristics of each muscle, different current and will be applied.~P11th program to ECRL and APL : 65 Hz. 200 μs, P13th program to ECRB and FCR 50 Hz, 200 μs will be applied. Exercises includes intrinsic and extrinsic muscle strengthening, stabilization exercises and dart exercises, wrist neuromuscular exercises and perturbation exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training (Control Group)
Description: Patients in the control group will have face-to-face exercise programs with a physiotherapist for a total of 24 sessions of 15 repetitions 3 days a week for 8 weeks. Exercises will be performed 3 days a week with a physiotherapist. On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises.~Exercise training includes intrinsic and extrinsic muscle strengthening, wrist stabilization exercises, dart exercises, wrist neuromuscular exercises using different materials, reactive muscle control, perturbation exercises.~Exercises will be at the limit of pain. Until the 6th month, overloading, strong gripping, weight transfer, rotations and lifting heavy objects should be avoided. Rehabilitation with functional range of motion is important. Exercises will be performed with a physiotherapist 3 days a week. On the other days, patients will be asked to perform 3 sets of 15 repetitions every day as home exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Neuromuscular Electrical Stimulation
Study: NCT04908735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants will receive ruxolitinib orally twice daily for 24 weeks.